Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 10/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30549428 | 0.85 | CA1 (0.52) | CA2CA1ARENPP2CYP19A1 | |
| SCHEMBL29071486 | 0.85 | CA1 (0.52) | CA2CA1ARENPP2CYP19A1 | |
| SCHEMBL585744 | 0.81 | ENPP2 (0.47) | CA2CA1ENPP2LPLLIPG | |
| SCHEMBL10269415 | 0.80 | CA2 (0.57) | CA2CA1ENPP2LPLLIPG | |
| SCHEMBL15272416 | 0.78 | AR (0.52) | AR | |
| SCHEMBL23788772 | 0.78 | AR (0.46) | ARCYP19A1ALDH1A1HPGD | |
| SCHEMBL177439 | 0.76 | CA2 (0.52) | CA2CA1ENPP2LPLLIPG | |
| SCHEMBL257894 | 0.76 | CA2 (0.52) | CA2CA1ENPP2LPLLIPG | |
| SCHEMBL2230653 | 0.74 | ENPP2 (0.76) | CA2CA1ENPP2CYP19A1ALDH1A1 | |
| SCHEMBL15096347 | 0.74 | AR (0.66) | ARCYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539253-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-9133131-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, P2RX3, CACNA1A | CA2 348/4885CA1 1353/4885AR 1402/4885 |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, P2RX3, CACNA1A | CA2 348/4885CA1 1353/4885AR 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.